Basal cell carcinoma near the eye most often appears as a small, pearly or waxy bump on the lower eyelid, sometimes with tiny blood vessels visible on its surface. Over half of eyelid BCCs start on the lower lid, and the growth is typically slow enough that people mistake it for a persistent stye or irritated patch of skin for months before seeking help. That delay matters, because BCC near the eye sits uncomfortably close to structures you cannot afford to lose, and catching it early is the difference between a minor outpatient procedure and extensive reconstructive surgery.
What Periocular BCC Actually Looks Like
If you are searching for pictures of BCC near the eye, you are probably trying to compare something on your own eyelid or a loved one’s face to known examples. The most common appearance is a firm, rounded nodule with a shiny or “pearly” surface. It often has a slightly raised, rolled border and may develop a small crater or ulcer in the center as it grows. Fine red blood vessels (called telangiectasias) frequently thread across the surface, giving it a distinctive look that dermatologists learn to recognize on sight.
That said, not every periocular BCC looks the same. In a study of periocular BCC specimens, roughly two-thirds were the nodular subtype, about one in six were infiltrative, around one in eight were superficial, and a small fraction were micronodular. About a quarter of tumors contained more than one subtype in the same lesion.1PubMed. Histological subtypes of periocular basal cell carcinoma The infiltrative type is the most deceptive: instead of forming an obvious bump, it can look like a flat, slightly scarred area of skin, sometimes resembling nothing more than a patch of mild eczema or a slow-healing wound. The superficial type tends to be a thin, reddish, scaly plaque. If you are comparing photos online, keep in mind that not all BCCs will match the classic “pearly nodule” description.
A few warning signs are worth memorizing. A sore on the eyelid that bleeds, crusts over, and then reopens repeatedly is suspicious. So is any new growth near the eye that does not go away within a few weeks, or a patch of skin that looks like a scar even though you never injured the area. Eyelash loss in a small zone is another red flag, because the tumor can destroy hair follicles as it expands.
Why the Lower Eyelid Gets Hit Hardest
More than half of eyelid BCCs initially occur on the lower lid.2PubMed Central. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment The inner corner of the eye (the medial canthus) is the second most common spot, followed by the upper eyelid and then the outer corner. The lower lid’s vulnerability makes sense when you consider sun exposure: the lower lid faces upward and catches reflected UV from the ground, water, and pavement throughout the day. The upper lid, by contrast, spends much of its time tucked under the brow.
The medial canthus deserves special attention because tumors there can be tricky. The skin is thin, the tear drainage system runs right beneath it, and the anatomy is complex. BCC at the inner corner tends to recur more often after treatment than BCC on the lower lid, partly because the tumor can extend along the tear duct lining before anyone realizes how far it has spread.
Who Is Most at Risk
Cumulative UV exposure is the single biggest driver. In a large case-control study, people with high occupational UV exposure had roughly twice the risk of developing BCC in sun-exposed areas compared with people who had little or no occupational UV exposure.3PubMed Central. Basal cell carcinoma risk and solar UV exposure in occupationally relevant anatomic sites: do histological subtype, tumor localization and Fitzpatrick phototype play a role? A population-based case-control study A separate clinical study found that over 80% of BCCs occurred on sun-exposed skin, and the vast majority of patients had fair complexions.4PubMed Central. A Clinical Study of Basal Cell Carcinoma
Beyond UV, other factors raise your odds: a history of sunburns in childhood, a weakened immune system (from medications or illness), previous radiation therapy to the face, and older age. Fair-skinned individuals who burn easily and tan poorly are disproportionately affected. If you have had one BCC anywhere on your body, your risk of developing another one in the future is substantially higher than the general population’s, and the periocular area is one of the places it can show up next.
Easily Confused With a Stye or Chalazion
One of the underappreciated dangers of BCC near the eye is that it can mimic benign conditions. A study examining over a thousand cases clinically diagnosed as chalazion (a common, harmless eyelid cyst) found that about 6% were actually something else. Among those misdiagnosed cases, some turned out to be malignant, including basal cell carcinoma.5Eye. Accuracy of the clinical diagnosis of chalazion Older research has also documented how the appearance of eyelid BCC can overlap with other common lid lesions, making clinical diagnosis alone unreliable.6The Journal of Dermatologic Surgery and Oncology. Basal‐Cell Carcinomas of the Eyelids: Pitfalls in Diagnosis and Therapy
The practical takeaway is straightforward: any eyelid lump that persists beyond a few weeks, especially in someone over 40 with a history of sun exposure, deserves a professional evaluation. A chalazion usually resolves with warm compresses. A BCC will not. If a bump keeps coming back, bleeds easily, or slowly changes shape, push for a biopsy rather than another round of warm compresses. Early clinical diagnosis was correct only about 60% of the time in one long-term review, underscoring why tissue examination matters.7JAMA Network (Archives of Ophthalmology). Basal Cell Carcinoma of the Eyelids: A Long-Term Follow-up Study
Mohs Surgery and Why It Dominates Treatment
Surgery is the standard treatment for BCC near the eye, and Mohs micrographic surgery has become the preferred technique for this location. The procedure removes tissue in thin layers, and each layer is examined under a microscope before more tissue is taken. This lets the surgeon trace irregular tumor extensions while sparing as much healthy tissue as possible, which is especially valuable around the eye where every millimeter counts.
Outcomes with Mohs surgery are strong. An Australian database study found a recurrence rate of about 2% for periocular BCC treated with Mohs, with zero recurrences among tumors that had never been treated before. All seven recurrences in that study involved tumors that had already come back after prior treatment.8PubMed. The Australian Mohs database, part II: periocular basal cell carcinoma outcome at 5-year follow-up A separate series reported a recurrence rate of about 1.6% for primary tumors versus 20% for tumors being re-treated after a prior failed excision.9PubMed. Management of periocular basal cell carcinoma by Mohs micrographic surgery Another study following patients for an average of about four years reported a 5% recurrence rate overall.10PubMed. Mohs’ micrographic surgery for basal cell carcinomas on the eyelids and medial canthal area. II. Reconstruction and follow-up
The pattern across studies is consistent: if your periocular BCC has never been treated before, Mohs gives you excellent odds of a cure. Previously recurrent tumors are harder to clear, in part because scar tissue from earlier surgery can mask the tumor’s true borders.
Rebuilding the Eyelid After Removal
One of the biggest concerns patients have is what happens to the eyelid after the tumor is cut out. The answer depends on the size and location of the defect. Small wounds may heal on their own or with direct stitching. Larger defects require flaps of nearby skin or, in some cases, grafts from other parts of the body. The goals of reconstruction are to restore normal eyelid closure and blinking, protect the eye’s surface, and achieve a reasonable cosmetic result.11PubMed Central. Review of Eyelid Reconstruction Techniques after Mohs Surgery
Most reconstructions go well, but complications do happen. The one patients worry about most is ectropion, where the lower eyelid pulls away from the eyeball. A study found that larger defects, those involving both the cheek and eyelid, and certain facial bone structures were independent risk factors for developing ectropion after reconstruction.12PubMed Central. Risk Factors for Ectropion After Lower Eyelid and Cheek Reconstruction Following Mohs Micrographic Surgery Ectropion can cause tearing, dryness, and irritation, but it is often correctable with additional minor procedures if it does not resolve on its own.
Non-Surgical Options
Surgery is not always feasible. Some patients are too frail for an operation, have tumors in locations where surgery would be disfiguring, or simply refuse it. For these cases, a few alternatives exist, though none match surgery’s cure rates for invasive tumors.
Topical creams like imiquimod and fluorouracil have been tried on eyelid BCC. One study reported complete clinical clearance in most patients with both drugs, though imiquimod caused more local side effects, including redness, chemical irritation of the eye’s surface, and skin color changes.13PubMed. Long-term efficacy and safety of imiquimod 5% and fluorouracil 1% creams in medical monotherapy of complex eyelid basal cell carcinomas Another case series examining imiquimod and photodynamic therapy for periocular BCC found more modest clearance rates, with fewer than half of lesions achieving clinical clearance with imiquimod and a similar proportion with photodynamic therapy.14PubMed. Role of non-surgical therapies in the management of periocular basal cell carcinoma and squamous intra-epidermal carcinoma: a case series and review of the literature These treatments may work for superficial BCCs or for patients who cannot undergo surgery, but they generally are not first-line choices when the tumor sits close to the eye.
Radiation therapy is another option, particularly for elderly patients or those with health conditions that make surgery risky. It can control the tumor effectively, but potential long-term side effects near the eye include dry eye, eyelash loss, ectropion, cataracts, and in rare cases, damage to the optic nerve or retina.15Austin Journal of Clinical Ophthalmology. Radiation Therapy for Eyelid Basal Cell Carcinoma – A Case Report
Vismodegib for Advanced or Inoperable Tumors
When periocular BCC grows too large for simple surgery or invades the eye socket, a drug called vismodegib can be a game-changer. It works by blocking a cell-signaling pathway that the tumor depends on for growth. In a small case series of orbital and periocular BCCs treated with vismodegib, half achieved complete responses and half achieved partial responses with significant tumor shrinkage.16PubMed Central. Efficacy of Vismodegib (Erivedge) For Basal Cell Carcinoma Involving the Orbit and Periocular Area A broader literature review found overall clinical response rates ranging from roughly 68% to 100%, with complete response rates between 20% and 88%.17Cancer Treatment and Research Communications. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma
Vismodegib is not a casual medication. Common side effects include muscle cramps, taste disturbances, hair loss, and weight loss. In one review of 30 patients, four developed squamous cell carcinoma during treatment, a concerning finding that is still being studied.18PubMed. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma Still, for a patient facing the prospect of losing an eye to an aggressive tumor, the drug can shrink the cancer enough to make surgery possible. In one reported case, vismodegib reduced a locally advanced recurrent BCC sufficiently that the patient underwent surgical removal with clear margins, saving the orbit from the complete removal that would otherwise have been required.19PubMed. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma
When the Tumor Spreads Into Deeper Structures
BCC almost never metastasizes to distant organs, but it can be locally destructive in a way that few other cancers match. Near the eye, advanced tumors can invade the tear drainage system, the bones of the eye socket, and even the orbit itself. Researchers have documented BCC traveling along the mucosal lining of the tear ducts, reaching the nasal cavity without destroying the surrounding bone or cartilage.20PubMed. Invasion of the lacrimal system by basal cell carcinoma This kind of spread along mucosal surfaces has been confirmed in other case reports as well.21PubMed. Basal Cell Carcinoma Involving the Lacrimal Canaliculus: A Documented Mechanism of Tumor Spread
In a series of advanced periocular BCCs with orbital invasion, surgeons removed the lacrimal sac in half the cases due to suspected involvement of the tear drainage duct, and that invasion was confirmed in the majority of those patients.22PubMed Central. Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances Orbital exenteration, the complete removal of the eye and surrounding soft tissues, is the last resort for deeply invasive tumors. In an older long-term study, eight patients required exenteration, and half of those still experienced recurrence afterward. The overall tumor death rate in that series was 2%.7JAMA Network (Archives of Ophthalmology). Basal Cell Carcinoma of the Eyelids: A Long-Term Follow-up Study These cases are rare, but they illustrate why early treatment makes such a difference.
Why People Wait Too Long
Delay in seeking treatment is one of the most frustrating patterns in periocular BCC. Evidence suggests that denial is the main psychological reason people put off seeing a doctor about a non-melanoma skin cancer on the face, and that delay is directly associated with larger tumors at the time of diagnosis.23BMJ. Facial basal cell carcinoma A bigger tumor means a bigger surgery, a more complex reconstruction, and a higher risk of recurrence. People often rationalize the growth as a stye, a cyst, or just “dry skin,” particularly because periocular BCC tends to grow slowly enough that it does not seem urgent on any given day.
If you notice a persistent, slowly growing bump on or near your eyelid, especially if you are fair-skinned and have a history of sun exposure, get it checked. A biopsy is a quick in-office procedure, and the peace of mind is worth it even if the growth turns out to be benign.
Gorlin-Goltz Syndrome and Younger Patients
Most periocular BCC occurs in older adults, but there is a rare genetic condition where it shows up decades earlier. Nevoid basal cell carcinoma syndrome, also called Gorlin-Goltz syndrome, is an inherited disorder that predisposes people to developing multiple BCCs, often starting in their teens or twenties. It also causes jaw cysts, skeletal anomalies, and calcifications in the brain.24PubMed Central. Review of Ocular Manifestations of Nevoid Basal Cell Carcinoma Syndrome: What an Ophthalmologist Needs to Know
In a review of 105 consecutive patients with eyelid BCC at one center, four had Gorlin-Goltz syndrome. All four had a family history of the condition, and the average age at first BCC detection was 30 years, far younger than the typical patient. Three of the four had advanced eyelid tumors with orbital involvement by the time they were treated, two of whom required orbital exenteration.25PubMed. Basal cell carcinoma of the eyelid associated with Gorlin-Goltz syndrome For anyone developing multiple BCCs before age 40, or anyone with a family history of unusually early or numerous skin cancers, evaluation for this syndrome is warranted.
Emerging Imaging Without a Scalpel
Diagnosing periocular BCC still depends on biopsy, but non-invasive imaging is gaining ground as a way to evaluate suspicious lesions before cutting into them. Optical coherence tomography (OCT), which works similarly to ultrasound but uses light instead of sound, can visualize the layers of skin around the eye in fine detail. In studies of periocular BCC, OCT consistently identified the loss of the normal boundary between the skin’s top layer and the layer beneath it in every single case examined. It also spotted the dark, rounded tumor clusters within the skin in over 80% of cases.26PubMed Central. In Vivo Non-Invasive High-Resolution Imaging for the Evaluation of the Periocular Skin Area: A Comprehensive Review of the Literature OCT is not yet a replacement for tissue diagnosis, but it helps clinicians decide whether a lesion needs a biopsy and can sometimes map tumor margins before surgery, reducing the number of passes needed during Mohs.